We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01050062
First Posted: January 15, 2010
Last Update Posted: May 1, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Astellas Pharma Inc
Information provided by (Responsible Party):
Boehringer Ingelheim
December 24, 2009
January 15, 2010
December 18, 2012
January 30, 2013
May 1, 2014
January 2010
December 2011   (Final data collection date for primary outcome measure)
Incidence of Adverse Events (AEs) [ Time Frame: Week 52 ]
The number of patient with any AEs, patients with drug-related AEs
The primary end point is to confirm safety (Adverse event) and antihypertensive effect on the long term use in daily clinical settings. [ Time Frame: 12months ]
Complete list of historical versions of study NCT01050062 on ClinicalTrials.gov Archive Site
  • Systolic Blood Pressure (SBP) [ Time Frame: Week 0 and Week 52 ]
    SBP is observed at Week 0 and Week 52. The change of SBP from Week 0 to Week 52 is calculated.
  • Diastolic Blood Pressure (DBP) [ Time Frame: Week 0 and Week 52 ]
    DBP is observed at Week 0 and Week 52. The change of DBP from Week 0 to Week 52 is calculated.
  • Target Blood Pressure Achievement Rate [ Time Frame: Week 52 ]
    The proportion of the patients with target blood pressure in 52 weeks administrative period. Target blood pressure is defined as 'Guidelines for the management of hypertension (JSH2009)': less than 140/90 (SBP/DBP) mmHg for >= 65 years old or cerebrovascular disorder patient; less than 130/80 in diabetes, chronic kidney disease or myocardial infarction patient; less than 130/85 mmHg for others patient.
  • Blood Pressure Normalised Rate [ Time Frame: Week 52 ]
    The proportion of the patients with normalized blood pressure in 52 weeks on administrative period. Normalized blood pressure is defined less than 140/90 (SBP/DBP) mmHg according to JSH2009
Not Provided
Not Provided
Not Provided
 
Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use
Post Marketing Surveillance on Long Drug Use of Micombi Combination Tablets in Patients With Hypertension
The survey is conducted to collect safety and effectiveness information in Hypertensive patients treated with Micombi Tablets on the long term use in daily clinical settings in Japan.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
1000
Hypertension
  • Drug: Telmisartan 80mg
    Combination tablet
  • Drug: Telmisartan 40mg
    Combination tablet
  • Drug: Hydrochlorothiazide 12.5mg
    Combination tablet
  • Micombi® Combination Tablet AP
    Interventions:
    • Drug: Telmisartan 40mg
    • Drug: Hydrochlorothiazide 12.5mg
  • Micombi® Combination Tablet BP
    Interventions:
    • Drug: Telmisartan 80mg
    • Drug: Hydrochlorothiazide 12.5mg
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1452
December 2011
December 2011   (Final data collection date for primary outcome measure)

Inclusion criteria:

Hypertensive patients who have never taken Micombi Tablets.

Exclusion criteria:

Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT01050062
502.542
Not Provided
Not Provided
Not Provided
Boehringer Ingelheim
Boehringer Ingelheim
Astellas Pharma Inc
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
April 2014